Patent US6159751A successfully refreshed from Google Patents.
← Back to Patent Explorer
US6159751A Expired / Lapsed US ⏱️ 0.0 years remaining

Development of DNA probes and immunological reagents of human tumor associated antigens

Assignee: Columbia University
•
Filing: 1995-06-05
•
Granted: 2000-12-12
•
Expires: 2015-06-05
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract This invention provides a method for preparing a hybridoma cell line which produces a monoclonal antibody which specifically recognizes and binds to a tumor associated antigen which comprises: (a) cotransfecting a CREF-Trans 6 cell line with DNA isolated from a neoplastic, human cell and a plasmid which encodes a selectable or identifiable trait; (b) selecting transfected cells which express the selectable or identifiable trait; (c) recovering the cells so selected in step (b); (d) injecting the cells so recovered in step (c) into a suitable marine host; (e) maintaining the resulting first murine host for a period of time effective to induce the cells injected in step (d) to form a tumor in the murine host; (f) isolating the tumor formed in step (e); (g) obtaining tumor cells from the isolated tumor in step (f); (h) coating the tumor cells obtained in step (9) with an antiserum generated against the CREF Trans-6 cell line (i) injecting the antiserum-coated cells from step (h) into a plurality of suitable second murine hosts; (j) screening the resulting second hosts from step (i) to identify hosts which produce serum reactive with the neoplastic human cell; (k) removing spleens from the second hosts so identified in step (j); (l) preparing from the spleens so removed in step (k) hybridomas; and (m) recovering therefrom a hybridoma cell line which produces a monoclonal antibody which specifically recognizes and binds to the tumor associated antigen.

Inventors

  • 👤 Paul B. Fisher

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-06 12:59
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/32; C07K14/00; C07K14/82; C07K16/28; C07K16/30; C07K16/3069; C12; C12Q; C12Q1/00; C12Q1/68; C12Q1/6876; C12Q1/6883; C12Q1/6886; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/808; Y10S530/809

Claims Analysis

Total Claims: 5
Claim 1
Independent Claim 240 words
A method for preparing a hybridoma cell line which produces a monoclonal antibody which specifically recognizes and binds to a tumor associated antigen which comprises: a) cotransfecting a CREF-Trans 6 cell line (ATCC Accession No. CRL 10584) with DNA isolated from a neoplastic, human cell and a plasmid which encodes a selectable or identifiable trait; b) selecting transfected cells which express the selectable or identifiable trait; c) recovering the cells selected in step (b); d) injecting the cells so recovered in step (c) into a suitable first murine host; e) maintaining the resulting first murine host for a period of time effective to induce the cells injected in step (d) to form a tumor in the first murine host; f) isolating the tumor formed in step (e); g) obtaining tumor cells from the isolated tumor in step (f); h) coating the tumor cells obtained in step (g) with an antiserum generated against the CREE Trans-6 cell line; i) injecting the antiserum-coated cells from step (h) into a plurality of suitable second murine hosts; j) screening the resulting second hosts from step (i) to identify hosts which produce serum reactive with the neoplastic, human cell; k) removing spleens from the second hosts so identified in step (j); l) preparing from the spleens so removed in step (k) hybridomas; and m) recovering therefrom a hybridoma cell line which produces a monoclonal antibody which specifically recognizes and binds to the tumor associated antigen.
Claim 2
Independent Claim 240 words
A method for preparing a hybridoma cell line which produces a monoclonal antibody which specifically recognizes and binds to a tumor associated antigen which comprises: a) cotransfecting a CREF-Trans 6 cell line (ATCC Accession No. CRL 10584) with DNA isolated from a neoplastic, human cell and a plasmid which encodes a selectable or identifiable trait; b) selecting transfected cells which express the selectable or identifiable trait; c) recovering the cells selected in step (b); d) injecting the cells so recovered in step (c) into a suitable first murine host; e) maintaining the resulting first murine host for a period of time effective to induce the cells injected in step (d) to form a tumor in the first murine host; f) isolating the tumor formed in step (e); g) obtaining tumor cells from the isolated tumor in step (f); h) coating the tumor cells obtained in step (g) with an antiserum generated against the CREE Trans-6 cell line; i) injecting the antiserum-coated cells from step (h) into a plurality of suitable second murine hosts; j) screening the resulting second hosts from step (i) to identify hosts which produce serum reactive with the neoplastic, human cell; k) removing spleens from the second hosts so identified in step (j); l) preparing from the spleens so removed in step (k) hybridomas; and m) recovering therefrom a hybridoma cell line which produces a monoclonal antibody which specifically recognizes and binds to the tumor associated antigen.
Claim 3
Dependent Claim 15 words
A method of claim 1, wherein the neoplastic, human cell is a metatastic tumor cell.
Claim 4
Dependent Claim 16 words
A method of claim 1, wherein the neoplastic human cell is a human prostatic carcinoma cell.
Claim 5
Dependent Claim 47 words
A method of producing a monoclonal antibody which specifically recognizes and binds to a cell surface antigen associated with a neoplastic, human cell which comprises: (a) producing a hybridoma according to the method of claim 1; and (b) recovering from the hybridoma so produced the monoclonal antibody.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2003-12-12 2004-06-12 2004-12-12 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2007-12-12 2008-06-12 2008-12-12 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2011-12-12 2012-06-12 2012-12-12 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag